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ABSTRACT
Background: iPS reprogramming to model 'disease-in-a-dish has become an attractive approach to study disease mechanisms. However, a frank pathophysiological phenotype in iPSC-derived PD neurons remains to be shown. Objective/Hypothesis: The objective of this proposal is to accelerate the aging process of iPS-derived dopaminergic neurons with the goal of reproducing a Parkinson's disease (PD) specific phenotype in vitro. Specific Aim 1.
To generate vector constructs and to establish Dox-inducible iPSC lines that express the Hutchinson-Gilford progeria (HGPS) gene (mutant lamin A with an inframe loss of 150 nucleotides) and differentiate them into dopaminergic neurons. Deliverable of this aim is the introduction of mutant lamin A in iPSC lines and optimization of inducible expression of mutant lamin A in iPSCs and during the differentiation into dopaminergic neurons. Specific Aim 2.
To test whether iPSC-derived dopaminergic neurons transduced with mutant lamin A show changes in age-regulated genes at the mRNA and protein levels at different time-points during differentiation, thus exhibiting an accelerated aging. Deliverable of this aim is the assessment of specific age-related aging pattern of gene and protein expression in induced mutant lamin A modified iPSCderived neurons. Specific Aim 3. To test whether induced mutant lamin A cell lines differentiated into dopaminergic neurons exhibit hallmark pathology of PD, such as protein aggregation of alpha-synuclein, posttranslational modification, and signs of mitochondrial pathology. Deliverable of this aim is the assessment of the pathological PD-related phenotype in induced mutant lamin A modified iPSC-derived neurons. Study Design: This is an in vitro study of patient-specific iPSC-derived dopaminergic neurons in which truncated lamin A will be introduced to study cellular phenotypes under the hypothesis that cells under expression of lamin A will age faster than untreated cells. Relevance: Creation of iPSC lines from patients with PD that develop a disease phenotype would revolutionize research in PD and could produce more predictive disease models to enable the advancement of better candidates into clinical testing. If successful, the impact of this research project on the iPSC field could be enormous. It could remove one of the remaining roadblocks to using iPSC model for PD for the study of disease mechanism and drug development, which could bring us closer to finding the cause and cure for PD.
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Introduction
The objective of this study was to introduce the truncated lamin A gene, progerin, into patient-derived induced pluripotent stem cells using a doxycycline (Dox)-inducible expression system and differentiated them into dopaminergic neurons. The hypothesis is that mutant lamin A, which is causing clinically an premature aging syndrome called
Hutchinson-Gilford progeria, will accelerate the aging process in the culture dish and facilitate changes related to a PD phenotype.
The underlying goal of this proposal is to optimize the current cellular iPSC model of PD aimed at reproducing a pathological phenotype in a culture dish and establishing a 'disease-in-a-dish' model for PD.
By using the progeria gene to experimentally age the iPS-derived DA neurons, we hypothesize that these cells age faster and therefore adding this important 'risk factor for PD' to the culture system presumably without interfering with the known disease related mechanisms of PD. We are now in the process of growing the cells for the pRetroX-Tight-Pur-Progerin transfection and the pRetroX-Tight-Pur-GFP-Progerin transfection.
Body
We have encountered several issues that delayed the project: 1. the timeline estimations of the original grant were based on immortalized cancer cell lines that have a faster doubling time compared to stem cells which show a much slower growth. 2. human patient-derived stem cells are more vulnerable to virus and conditions needed to be optimized including the use of antibiotic resistant feeder cells that support the growth of the cells. 
Co-transfection of iPS lines with Tet-on and progerin:
Besides the outlined consecutive transduction of the transactivator and then the progerin gene, we are also currently performing a co-transfection with pRetroX-Tet-on and pRetroX-Tight-Pur-GFP-Progerin to establish double-stable iPS lines expressing the rtTA and GFP-Progerin proteins.
The project received a nine month no cost extension to complete the milestones. We are confident that we will complete the study in this time period.
Advancement of Neuronal differentiation
We had established a neuronal differentiation protocol using embryoid body differentiation to obtain neural progenitor cells (NPC) (Mak et al., 2012) using a combination of two small molecules (SMAD inhibitors). This has been a cumbersome protocol which was taking up to 8 weeks to derive NPCs.
We are now in the process to establish a new protocol without embryoid body differentiation to derive NPCs within 10-14 days (Figure 2 ). iPS cells are maintained in Neural induction media for 7 days, then dissociated and replated onto Matrigel. At passage 2, the cells were stained for the neuroprecursor marker nestin (Figure 2 , panel 6, red) and showed a very high conversion rate. This allows us to faster differentiate the clones once they are derived and will save time at Milestone 4 of the proposal. 
Establishment of aging markers
One goal of the proposal as part of Milestone 5, we want to define an age-related phenotype. One established marker is the expression of the tau isoform 3R and 4R (Iovino et al., 2010) . We are currently testing the expression in naïve or untransfected stem cell cultures in the alpha-synuclein triplication cell lines compared to the control lines and will have the assay optimized once the progerin lines are derived.
Key Research Accomplishments:
• Milestone 1 (month 1-2): generation of the drug-inducible construct using Clontech
Retro-X Tet-On advanced vector COMPLETED At this point, no publications or posters have been derived from the grant, however, an abstract is planned for 2013 annual meeting of Neuroscience Society (SFN).
Conclusions:
Creation of iPSC lines from patients with PD that develop a disease phenotype would revolutionize research in PD and could produce more predictive disease models to enable the advancement of better candidates into clinical testing.
Even though there has been a delay in the progress due to the difficulties of utilizing human patient-derived stem cells, we think that there is a great value in the derivation of these cell lines.
It will also allow us to study in more detail the recent findings of nuclear envelope changes in another genetic PD syndrome, LRRK2 parkinsonism (Liu et al., 2012) .
